Castle Biosciences
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting var...
Latest News
4 days ago · prnewswire.com
Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First CultureRegional honors in Houston, Arizona and Pittsburgh, national healthcare industry recognition and eight Culture Excellence awards bring Castle's 2026 Top Workplaces honors to 13 FRIENDSWOOD, Texas, Nov. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned regional Top Workplaces awards in Houston, Arizona and Pittsburgh, along with national recognition through the Top Workplaces Healthcare Industry award and eight Top Workplaces Culture Excellence awards. Based on employee feedback, these honors reflect Castle's continued commitment to creating a workplace where people feel valued, supported and connected to a shared purpose.
5 days ago · prnewswire.com
Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare ConferenceFRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, Dec. 2, 2026, at 8:10 a.m. Eastern time.
5 days ago · prnewswire.com
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC StagingSDPA analysis demonstrates DecisionDx-Melanoma can identify higher-risk patients within a traditionally low-risk population with thin melanomas Dermato-Onco2026 analysis supports the test's ability to provide individualized five-year recurrence-risk estimates in stage I–III melanoma FRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will present new data on DecisionDx-Melanoma at the Society of Dermatology Physician Associates (SDPA) 24th Annual Fall Dermatology Conference, taking place Nov. 11-15, 2026, in Hollywood, Florida, and the 3rd European Congress on Dermato-Oncology (Dermato-Onco2026), taking place Nov. 12-13, 2026, in Rotterdam, The Netherlands. More precise assessment of a patient's risk of melanoma recurrence or death can help clinicians tailor follow-up and surveillance to each patient's individual needs.
6 days ago · zacks.com
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to TradeThe consensus price target hints at a 37% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
11 days ago · marketbeat.com
What Castle Biosciences (CSTL) Said on Its Q3 Earnings CallCastle Biosciences NASDAQ: CSTL raised its full-year revenue outlook after reporting 24% third-quarter revenue growth, driven primarily by demand for its TissueCypher test.
11 days ago · seekingalpha.com
Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call TranscriptCastle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript
11 days ago · zacks.com
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue EstimatesCastle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.02 per share a year ago.
11 days ago · prnewswire.com
Castle Biosciences Reports Third Quarter 2026 ResultsDelivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2026.
20 days ago · prnewswire.com
Castle Biosciences to Participate in Upcoming Investor ConferencesFRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Wednesday, Nov. 18, 2026, at 12:30 p.m. Central time.
1 month ago · prnewswire.com
Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CSTL